MXPA02003079A - Metodo y composiciones para inhibir la formacion de adhesion. - Google Patents

Metodo y composiciones para inhibir la formacion de adhesion.

Info

Publication number
MXPA02003079A
MXPA02003079A MXPA02003079A MXPA02003079A MXPA02003079A MX PA02003079 A MXPA02003079 A MX PA02003079A MX PA02003079 A MXPA02003079 A MX PA02003079A MX PA02003079 A MXPA02003079 A MX PA02003079A MX PA02003079 A MXPA02003079 A MX PA02003079A
Authority
MX
Mexico
Prior art keywords
compositions
adhesion formation
inhibiting adhesion
inhibiting
methods
Prior art date
Application number
MXPA02003079A
Other languages
English (en)
Spanish (es)
Inventor
A Cheresh David
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MXPA02003079A publication Critical patent/MXPA02003079A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/045—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA02003079A 1999-09-23 2000-09-22 Metodo y composiciones para inhibir la formacion de adhesion. MXPA02003079A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40552299A 1999-09-23 1999-09-23
PCT/US2000/026095 WO2001021196A1 (en) 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation

Publications (1)

Publication Number Publication Date
MXPA02003079A true MXPA02003079A (es) 2004-04-21

Family

ID=23604048

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02003079A MXPA02003079A (es) 1999-09-23 2000-09-22 Metodo y composiciones para inhibir la formacion de adhesion.

Country Status (9)

Country Link
EP (1) EP1223962A4 (enExample)
JP (1) JP2003509468A (enExample)
KR (1) KR20020048941A (enExample)
CN (1) CN1399554A (enExample)
AU (1) AU781442B2 (enExample)
BR (1) BR0014222A (enExample)
CA (1) CA2384812A1 (enExample)
MX (1) MXPA02003079A (enExample)
WO (1) WO2001021196A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025685B1 (en) 2007-08-15 2013-06-19 Canadian Blood Services Monoclonal antibodies against BETA3 integrins
WO2018012605A1 (ja) 2016-07-13 2018-01-18 持田製薬株式会社 癒着防止用組成物
WO2019138583A1 (ja) * 2018-01-15 2019-07-18 持田製薬株式会社 癒着防止用組成物
KR102318958B1 (ko) * 2019-08-08 2021-10-27 고려대학교 산학협력단 인테그린 α2β1 억제제를 유효성분으로 포함하는 조직 유착 예방 또는 치료용 약제학적 조성물
US20230149503A1 (en) * 2020-03-31 2023-05-18 The Regents Of The University Of California Compositions and methods for treating dysregulated wound healing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
CA2302017C (en) * 1997-08-25 2007-01-30 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Also Published As

Publication number Publication date
AU781442B2 (en) 2005-05-26
WO2001021196A1 (en) 2001-03-29
CA2384812A1 (en) 2001-03-29
CN1399554A (zh) 2003-02-26
KR20020048941A (ko) 2002-06-24
JP2003509468A (ja) 2003-03-11
AU7985000A (en) 2001-04-24
BR0014222A (pt) 2003-02-25
EP1223962A1 (en) 2002-07-24
EP1223962A4 (en) 2004-01-21

Similar Documents

Publication Publication Date Title
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
MXPA02004671A (es) Conjugados de interferon gamma.
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
TR200103428T2 (tr) IMPDH enzim inhibitörleri.
MY122391A (en) Piperazine derivatives as 5-ht1b antagonists
AU2003303598A8 (en) Compositions, methods, and systems for inferring bovine breed
IL143700A0 (en) Methods and compositions for treatment of cell proliferative disorders
AR016751A1 (es) Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
DK1372686T3 (da) Fremgangsmåder og sammensætninger til peptidsyntese
MY124214A (en) Compositions for promoting crowth
TW200519110A (en) Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use
ES2162676T3 (es) Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
EE200100649A (et) A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks
BG64475B1 (bg) Ципразидонови соли
GB2352395A (en) Paroxetine methanesulfonate
BG103286A (en) Compositions and methods for ore dressing
HUP0300318A3 (en) Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
ZA993777B (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
ZA974542B (en) New amino acid derivatives and their use as thrombin inhibitors.
IL152111A0 (en) Tamandarin and didemnin analogs and methods of making and using them
HUP0105302A3 (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparation
MX9801987A (es) Nuevos derivados de aminoacido, su obtencion y su uso.
EP1244452A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
DK1207870T3 (da) Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf